Beurteilung eines Screeningverfahrens zur Bestimmung des HbA1c im Rahmen einer Untersuchung zur Sekundärprävention in Bezug auf das Disease-Management-Programm Koronare Herzkrankheit

Cardivascular diseases, especially coronary heart disease are the most frequent causes of death. For this reason it is important to treat modifiable risk factors as best as possible to improve secondary prevention. In 2003 the German Disease Management Program for coronary heart disease was introduced. Within the scope of this thesis it is analyzed in how far patients in the disease management program are treated in a better way than patients who do not take part in that program. Data of 38 patients were analyzed. 11 of these patients took part in the disease management program, 27 patients did not. It can be shown that in most parts there was no difference between both groups. Only blood lipids and some parts of medication were treated slightly more consequent within the DMP. The results are compared to the results of another study which was conducted by Bestehorn et al. [5] in 2009. About 45,000 patients were examined in order to compare patients participating in a DMP and patients who were treated outside the DMP. The results are similar to the results in the thesis at hand, however in the study of Bestehorn et al. the benefits for the patients who took part in the DMP were greater. Another aim of this thesis was the analysis of an immunoassay that allows easier measurement of the HbA1c in comparison to standardized measurement methods. The results show, that the new method is as exact as the standardized measurement. In addition it is as practicable as a blood glucose monitoring, i.e. it is a good method to identify diabetics and provide them with an appropriate therapy.